Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004340 · ClinicalTrials.gov registry record · Phase 2

Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis

A Phase 2 study of End Stage Renal Disease and Renal Osteodystrophy, sponsored by National Center for Research Resources (NCRR).

Completed
Registry status
Phase 2
Development phase
109
Enrollment target
1
Study location

NCT00004340: Completed Phase 2 study of End Stage Renal Disease and Renal Osteodystrophy, sponsored by National Center for Research Resources (NCRR).

NCT00004340 is a Phase 2 study of End Stage Renal Disease and Renal Osteodystrophy that has completed, run by National Center for Research Resources (NCRR). The registered enrollment target is 109 participants, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004340, a Phase 2 study of End Stage Renal Disease and Renal Osteodystrophy, has completed, sponsored by National Center for Research Resources (NCRR).

COMPLETED
Registry status
Phase 2
Development phase
109 participants
Enrollment target
1
Study location

Study Summary

OBJECTIVES: I. Evaluate the separate and combined skeletal effects of recombinant human growth hormone (GH) and calcitriol in patients with adynamic renal osteodystrophy. II. Assess whether calcium-regulated changes in parathyroid hormone secretion predict changes in bone formation. III. Characterize the response to GH in cancellous bone and in growth plate cartilage in patients with secondary hyperparathyroidism during calcitriol therapy.

Interventions

  • DRUG growth hormone
  • DRUG calcitriol

Study Locations (1)

California

  • University of California Los Angeles School of Medicine - Los Angeles

Trial Details

FieldValue
Enrollment Target 109 participants
Start Date 1995-06
Phase Phase 2

What the finished NCT00004340 record still lists

NCT00004340 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (87% lower).

The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 2 interventions - of which growth hormone is the first listed.

NCT00004340 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00004340 about?

NCT00004340 is a clinical study titled "Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis". OBJECTIVES: I. Evaluate the separate and combined skeletal effects of recombinant human growth hormone (GH) and calcitriol in patients with adynamic renal osteodystrophy. II. Assess whether calcium-regulated changes in parathyroid hormone secretion predict changes in bone formation. III. Character...

What is the current status of trial NCT00004340?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 1995-06.

What conditions does trial NCT00004340 study?

This clinical trial studies the following conditions: End Stage Renal Disease, Renal Osteodystrophy.

What interventions are being tested in trial NCT00004340?

The interventions under investigation include: growth hormone (DRUG), calcitriol (DRUG).

Who is sponsoring clinical trial NCT00004340?

This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00004340 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00004340's enrollment target sits among peer trials

109 32nd of 86 higher than 55 of 86 other End Stage Renal Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02421380 · 109 participants · NA

    Characterization of Hyperpolarized Pyruvate MRI Reproducibility

  • NCT04526600 · 109 participants · NA

    Fidgeting and Attentional and Emotional Regulation in ADHD

  • NCT04835584 · 109 participants · Phase 1

    KRT-232 and TKI Study in Chronic Myeloid Leukemia

  • NCT06626516 · 109 participants · Phase 1

    Tebentafusp-tebn With LDT in Metastatic UM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00004340, the US trial registry maintained by the National Library of Medicine. NCT00004340 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.